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Laura Cendron4, Rodolfo Berni1, Giuseppe Zanotti4 & Riccardo Percudani1
Urate oxidase (Uox) catalyses the first reaction of oxidative uricolysis, a three-step enzymatic pathway 
that allows some animals to eliminate purine nitrogen through a water-soluble compound. Inactivation 
of the pathway in hominoids leads to elevated levels of sparingly soluble urate and puts humans at risk 
of hyperuricemia and gout. The uricolytic activities lost during evolution can be replaced by enzyme 
therapy. Here we report on the functional and structural characterization of Uox from zebrafish and 
the effects on the enzyme of the missense mutation (F216S) that preceded Uox pseudogenization in 
hominoids. Using a kinetic assay based on the enzymatic suppression of the spectroscopic interference 
of the Uox reaction product, we found that the F216S mutant has the same turnover number of the 
wild-type enzyme but a much-reduced affinity for the urate substrate and xanthine inhibitor. Our results 
indicate that the last functioning Uox in hominoid evolution had an increased Michaelis constant, 
possibly near to upper end of the normal range of urate in the human serum (~300 μM). Changes in 
the renal handling of urate during primate evolution can explain the genetic modification of uricolytic 
activities in the hominoid lineage without the need of assuming fixation of deleterious mutations.
Urate oxidase (uricase, Uox) catalyses hydroxylation of urate to give 5-hydroxyisourate (HIU)1. This is the first 
and rate-limiting step of uricolysis, a three-step enzymatic pathway present in both prokaryotes and eukaryotes 
that converts urate into the more soluble (S)-allantoin2. Uox is an enzyme of medical and evolutionary impor-
tance. Its loss by pseudogenization during primate evolution3,4, caused the inactivation of the uricolytic pathway 
in hominoids (lesser and great apes, including humans). The inability to degrade urate coupled with an effective 
renal reabsorption system for this compound leads to elevated concentration of urate in blood5,6, arguably the 
most noticeable difference in hematological parameters between hominoids and other mammals. Excess of serum 
urate (hyperuricemia) is commonly defined in humans for concentrations exceeding 400 μ M; however, the nor-
mal concentrations of urate in the human serum (160–360 μ M) are about ten times higher than in mammals 
possessing functional Uox7–9. The metabolic differences in purine degradation between hominoids and other 
mammals are illustrated by the consequences of deficiency of hypoxanthine-guanine phosphoribosyltransferase 
(HPRT), an enzyme that recycles free purines into the corresponding nucleotides. Inborn deficiency of this 
enzyme in humans due to mutation in the HPRT1 gene causes early-onset severe hyperuricemia and a constella-
tion of neurological symptoms that characterize the Lesch-Nyhan syndrome10,11. Conversely, in the mouse, com-
plete absence of the HPRT enzyme due to experimental gene inactivation does not cause hyperuricemia and is 
virtually asymptomatic12. In humans, the intravenous administration of urate oxidase, replacing the Uox activity 
lost in hominoid evolution, is used in the enzymatic therapy of severe hyperuricemia and to prevent the burst of 
uric acid accompanying tumor lysis after certain chemotherapy treatments13.
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Mammals able to degrade urate possess the classical type of urate oxidase (EC 1.7.3.3). The oldest known 
structure of the enzyme is a tetramer of the tunnelling (T) fold domain able to catalyse urate oxidation without the 
help of cofactors14,15. Complete bacterial genomes have revealed a surprising variety of proteins with independent 
origin involved in urate oxidation. Besides the cofactorless Uox, the prevalent form in Gram-positive bacteria, 
there are two distinct flavoenzymes16,17 and an integral membrane cytochrome c-containing protein, which is the 
prevalent Uox in Gram-negative bacteria18. Plants, fungi and animals possess the same cofactorless Uox, suggest-
ing an ancient origin for this protein in eukaryote evolution.
In animals, uricolysis occurs in peroxisomes by the consecutive action of Uox, HIU hydrolase (Urah), and 
2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) decarboxylase (Urad). Genes orthologous to char-
acterized Uox, Urah and Urad, are found in basal metazoan lineages such as cnidarians, consistent with the 
presence of the uricolytic pathway in the last common ancestor of metazoa. These genes have survived one billion 
years of animal evolution before being inactivated in hominoids. Although the human genome is littered with 
thousands of pseudogenes19, non-duplicated pseudogenes such as Uox are rare (< 1%). At variance with the inac-
tivation of copies of functional genes deriving from segmental duplications or retroposition, the loss of “unitary” 
or “long-established” genes20,21 results in the loss of a specific function in the organism. This is a rare event in 
mammalian genomes that is likely to be driven by adaptive evolution22. Genome-wide surveys have identified 
a very limited number of unitary gene losses (six or seven genes, including Uox) in the hominoid lineage20,21. 
Loss of the Uox activity determined dismissal and pseudogenization of the two other genes involved in urate 
degradation, Urah and Urad23, providing the only known example of inactivation of a metabolic pathway in the 
hominoid lineage.
The causes and mechanisms of Uox pseudogenization have been intensively investigated. The pseudo-coding 
sequence of the Uox gene in extant hominoids contains multiple stop codons. However, the lack of a common 
nonsense mutation in the sequence of great and lesser apes led to the proposal that the gene was independently 
inactivated in the two lineages3,4. More recently, it has been suggested that Uox inactivation was a gradual process 
driven by the accumulation of deleterious missense mutations24,25. Several amino acid substitutions occurred in 
the Uox sequence during the primate phylogenetic history. When experimentally introduced in the sequence of 
a functional Uox, many of these mutations were found to impair protein solubility and/or activity. However, of 
particular relevance for gene inactivation are the mutations that were fixed in the branch leading to the common 
ancestor of great and lesser apes (approximately between 30 and 20 Mya). A single missense mutation, Phe→ Ser 
at codon 222, has been precisely identified in the hominoid lineage25.
In previous studies, the Urah and Urad enzymes of the urate degradation pathway have been characterized in 
the model vertebrate zebrafish (Danio rerio). With respect to the mammalian counterpart2, the isolated proteins 
from zebrafish demonstrated higher solubility and stability and were amenable to structure-function analysis26,27. 
Here we describe the functional characterization of urate oxidase from Danio rerio (DrUox) through a kinetic 
assay that allows the determination of the enzymatic activity under physiological pH and salt conditions. The 
information on the DrUox structure was used as a framework for the understanding of the catalytic properties 
of the enzyme in comparison with an artificial variant (F216S) in which the same Phe→ Ser substitution that 
occurred in hominoid evolution was introduced by site-directed mutagenesis.
Results
The Phe→Ser mutation and the inactivation of the urate degradation pathway in hominoids. 
We determined the exon/intron structure of Uox genes and pseudogenes in primates through comparison 
between the Macaca fascicularis protein sequence and primate genomic DNA sequences, allowing for non-
sense, frameshift, and splice-site mutations28 (Supplementary Fig. S1). To infer the mutations that occurred in 
the Uox gene in the hominoid lineage we obtained sequence information for the Uox locus from 16 primate 
species with assembled genomes (6 hominoid and 10 non-hominoid species). The sampling of hominoid spe-
cies was completed by mapping whole genome sequences (WGS) short reads of four gibbon species (Hylobates 
moloch, Hylobates pileatus, Symphalangus syndactylus, Hoolock leuconedys) on the reference Nomascus leucogenys 
assembled genome. This procedure recovered > 90% of the Uox pseudoexonic sequence of the gibbon species 
(Supplementary Fig. S2), allowing a representation of the eight extant genera of hominoids in the dataset.
The maximum-likelihood reconstruction of ancestral Uox sequences along the primate tree, identified five 
accepted mutations of the Uox coding sequence in the branch leading to last common ancestor of extant hom-
inoids (Fig. 1). According to previous analysis25, F222S is the only sense mutation which occurred along this 
branch. However, the analysis of ancestral character states also identified a probable nonsense mutation (R107*) 
before the split of great and lesser apes (Fig. 1a,b). A stop codon is not found at position 107 of the Uox sequences 
of human and chimpanzee (Fig. 1a). Nevertheless, the onset of this mutation after the common ancestor of extant 
hominoids would require three independent mutations in the branches leading to gibbons, Pongo, and Gorilla 
(Supplementary Fig. S3). The presence of an Arg codon at this position in human and chimpanzee can be due 
to reversal of the mutation or to incomplete lineage sorting of a polymorphic allele, a phenomenon commonly 
observed in ape phylogeny4,29.
The primate dataset of Uox sequences was also used for an analysis of the selection pressure acting on the 
Uox gene during evolution, as inferred by calculating the rate of non-synonymous (dN) and synonymous (dS) 
mutations along the phylogenetic tree. Models with no variation of the dN/dS ratio and models assuming one or 
more than one persistent variations along branches were compared through the likelihood ratio test. If a single 
rate variation is assumed along the primate tree, the best likelihood is obtained with a change of dN/dS in the 
hominoid lineage (Table 1); this 2-rates model is significantly better than the 1-rate model. The model with two 
independent variations in the gibbon and great apes lineages (3-rates) is slightly better than the 2-rate model, 
while other models are not significantly better than the 3-rate model. However, these models consistently indicate 
that the Uox gene was under strong selection pressure during primate evolution, including most of the branch 
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leading to hominoids (Fig. 1a). Accordingly, on this branch a large excess of synonymous over sense mutations 
(3:1) is observed with respect to the proportion of synonymous and non-synonymous sites in the Uox sequence 
Figure 1. Phe→Ser mutation and the inactivation of the urate degradation pathway in hominoids. 
 (a) Chronogram of primate phylogeny based on multilocus analysis58; a polytomy was introduced to reflect 
uncertainties in the branching order of gibbon genera29,60. The tree was used as a framework for Bayesian 
reconstruction59 of ancestral Uox sequences and the ratio of non-synonymous/synonymous substitution 
rates (dN/dS). Posterior probabilities of nucleotide positions differing between the last common ancestors of 
Catarrhini and hominoids are shown in the inset. The single missense substitution in the hominoid lineage is 
indicated on the relevant branch (positions are according with the M. fascicularis sequence); the dashed line 
indicates uncertainty in dating the mutation along the branch. (b) The reconstructed Uox sequence of the 
Cathatrrini last common ancestor (node_C) compared with the sequence of the hominoid ancestor (node_H) 
using the sequence of M. fascicularis as a reference. Synonymous (gray), missense (yellow), and nonsense 
mutations (pink) with respect to the reference sequence are shown. Mutations which occurred along the branch 
connecting the two ancestral nodes are framed.
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4Scientific RepoRts | 6:38302 | DOI: 10.1038/srep38302
(249:671). Overall, the dN/dS analysis is consistent with relaxation of the selection pressure and pseudogenization 
of the Uox gene near the split of great and lesser ape (about 20 Mya). The F216S variant can thus be considered the 
last functioning Uox in hominoid evolution.
Zebrafish urate oxidase (DrUox) expression and activity assay. The zebrafish (Danio rerio) urate 
oxidase (chr11: 8151055.8158017) encodes a protein of 298 aa with a C-terminal tripetide (ARM) corresponding 
to the type 1 peroxisome-targeting signal. The unmodified DrUox coding sequence was overexpressed in E. coli 
and the corresponding protein purified to near apparent homogeneity using a dedicated xanthine-agarose col-
umn. The DrUox activity was measured in vitro using a kinetic assay based on the enzymatic suppression of the 
spectrophotometric interference of the Uox reaction product (Fig. 2).
The direct monitoring of the decay of the urate signal at 292 (or sometimes 293) nm is a widely used assay 
of the Uox activity25,30,31. However, it was recognized early14,31 that the unstable product of urate oxidation, 
5-hydroxyisourate (HIU), absorbs at this wavelength interfering with the measurement. The extinction coeffi-
cient of HIU at 292 nm is about 50% of that of urate (Fig. 2a,b and supplementary Fig. S4), producing a substantial 
error on the initial velocity estimate (Fig. 2c); moreover, the decay velocity of HIU is influenced by the reaction 
conditions (i.e. buffer and pH), producing false dependencies of the Uox reaction14. To alleviate the interference 
on the measurement at 292 nm, the Uox assay is often conducted in borate (B(OH)3) buffer at high pH, conditions 
that cause a more rapid decay of HIU28,31.
The use of HIU hydrolase (Urah) in a physiological potassium phosphate (KP) buffer (100 mM, pH 7.6) ena-
bled the elimination of the interference at 292 nm by catalysing the conversion of HIU to OHCU, a compound 
that has negligible absorbance at this wavelength (Fig. 2a,b). Urah is a very active enzyme (specific activity: 
230 ± 6 μ mol min−1 mg−1), and we found that a Urah:Uox molar ratio of 1:1 (> 10-fold excess of enzyme units) 
is sufficient to eliminate HIU interference and attain the maximum initial velocity (Fig. 2d). In our reaction 
conditions, this initial velocity was about 7-fold higher than that measured in the absence of Urah in phosphate 
buffer and 1.5-fold higher than that measured in borate (Fig. 2e), as the use of this nonphysiological buffer did not 
completely eliminate the HIU interference (Fig. 2f).
At variance with the reaction curve obtained with Uox alone, the curve in the presence of Urah could be fitted 
with a simple model of enzymatic disappearance of substrate32 (Supplementary Fig. S5). The comparison of the 
decrease in absorbance at 292 in the absence of Urah with the curve resulting from the combination of urate 
decrease and HIU formation and decay shows that most of the difference between the two reaction progression 
curves of Fig. 2c can be explained by the HIU interference at 292 nm. However, the experimental kinetics in the 
absence of Urah is appreciably slower than that predicted based on the absorbance of HIU. In addition, fitting of 
the kinetics of HIU formation monitored at 320 nm suggested that urate is degraded with the same Vmax as in the 
presence of Urah, but with a higher apparent KM, consistent with product inhibition. The combination of urate 
disappearance and HIU formation kinetics with an increased KM reproduced well the experimental behavior of 
the Uox reaction in the absence of Urah (Supplementary Fig. S5).
Reaction kinetics and inhibition mechanism of wt DrUox and F216S mutant. To examine the 
consequences of the Phe→ Ser mutation which occurred in hominoid evolution on the catalytic properties of 
DrUox, the F216S mutation (corresponding to F222S in the hominoid sequence) was introduced by site-directed 
mutagenesis. A difference between the wild-type and mutant proteins emerged during purification; at variance 
with the wt Uox, the F216S variant was unable to bind the xanthine-agarose column (Fig. 3a). Because of the 
impossibility of using the specific affinity column for F216S purification, a polyhistidine tag was added to the 
N terminus of both the wt and mutant proteins to allow purification by metal affinity chromatography. The 
His-tagged proteins were purified to near apparent homogeneity in a single chromatographic step. Comparison 
of the untagged and His-tagged wt proteins revealed no substantial differences in the enzymatic activity.
The rate of catalysis of the wt and mutant proteins subjected to the same purification procedure was measured 
at increasing substrate concentrations using the above-described spectrophotometric assay in the presence of 
DrUrah. Both enzymes exhibited Michaelis-Menten kinetics (Fig. 3b). The F216S protein had a 25-fold increased 
KM (280 μ M) with respect to the wt protein (11 μ M). By contrast, the same turnover number (kcat ≈ 4 s−1) was 
observed for the two proteins (Table 2). This indicates that the effect of the Phe→ Ser mutation on the protein 
catalytic efficiency depends on a decreased affinity for the urate substrate. Similarly, a decreased affinity for xan-
thine, a known inhibitor of the Uox reaction14, was suggested by the lack of binding of the F216S mutant to 
the xanthine-agarose column. Xanthine proved to be a competitive inhibitors for the wt and mutant enzymes, 
Model
dN/dS on branchesa
Haplorrhini Simiiformes Catarrhini Cercopithecini Hominoidea Hylobatidae Hominidae Log likelihood LRT
H0: (1 rate) 0.33 = Haplor. = Haplor. = Haplor. = Haplor. = Haplor. = Haplor. − 2881.94
H1: (2 rates) 0.17 = Haplor. = Haplor. = Haplor. 1.17 = Homino. = Homino. − 2856.90 1.5E-12b
H2: (3 rates) 0.17 = Haplor. = Haplor. = Haplor. = Haplor. 1.25 1.38 − 2854.75 0.04c
H3: (4 rates) 0.17 = Haplor. = Haplor. = Haplor. 0.12 1.26 1.38 − 2854.69 0.72d
H4: (7 rates) 0.18 0.18 0.07 0.15 0.12 1.26 1.38 − 2854.25 0.83e
Table 1.  Parameter estimates under models of variable dN/dS ratios of the Uox gene among primate 
lineages. adN/dS on branches leading to the common ancestor of the indicated lineages in accordance with the 
tree shown in Fig. 1. bH1 vs. H0; df = 1. cH2 vs. H1; df = 1. dH3 vs. H2; df = 1. eH4 vs. H3; df = 3.
www.nature.com/scientificreports/
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affecting the apparent KM, but not the maximal velocity of the reaction (Fig. 3c). However, the inhibition constant 
(Ki) for xanthine was about one order of magnitude higher for the mutant enzyme with respect to the wild-type 
(Table 2).
No substantial differences in the population of oligomers were observed for the wt and mutant DrUox, with 
a large prevalence of the tetrameric assembly for both proteins (Fig. 4a). For both enzymes, we observed a lin-
ear dependency of the enzymatic activity on the concentration of the protein in solution (Fig. 4b), thus ruling 
out a protein concentration-dependent shift in the equilibrium among functionally different quaternary species. 
However, the F216S mutant appeared to be more prone to thermal inactivation at temperatures ≥ 40 °C, and less 
soluble in highly concentrated solutions. When crystallization solutions were prepared, the wt protein could be 
concentrated up to 10 mg/ml, while the F216S protein started to precipitate at ~2 mg/ml concentration.
F216 in the DrUox crystal structure. The crystal structure of DrUox was obtained at 2.8 Å resolution 
(Supplementary Table S1) with a continuous electron density from Gly8 to Pro294. Structures of the T-fold urate 
oxidase have been determined previously for bacterial proteins30,33,34, the fungus Aspergillus flavus15, and a ‘fossil’ 
euarchontoglires (primates and rodents) protein reconstructed through phylogenetic inference25. The highest 
structure similarity of the DrUox monomer is with the fossil euarchontoglires protein (PDB ID 4MB8; rmsd 
0.8 Å) and the lowest similarity is with the Uox from Bacillus spp. (PDB ID 3WLV; rmsd 2.5 Å).
The DrUox structure (Fig. 5) shows the typical T-fold with a homotetramer organized as a dimer of dimers 
joining head-to-head to form the functional tetramer. Each monomer contains two tandem repeats of the T-fold 
domain forming an antiparallel β 8-sheet with four main α -helices located at the concave side of the sheet. Two 
Figure 2. Enzymatic suppression of the spectrophotometric inference in the Uox reaction. (a) Scheme of the 
enzymatic conversion of urate into allantoin; molar extinction coefficients (mM−1 cm−1) at 292 nm, pH 7.6, are 
indicated. (b) Experimental urate UV spectrum and calculated HIU and OHCU spectra in the region between 
220 and 340 nm; approximate spectra were obtained by kinetic analysis56 of the time resolved spectra of the Uox 
reaction (supplementary Fig. S4). (c) Decrease of absorbance at 292 nm of 0.1 mM urate with the addition 
of DrUox (0.9 μ M) in the absence (black curve) and in the presence (red curve) of equimolar DrUrah. (d) Uox 
activity as monitored by decrease of absorbance at 292 nm in the presence of different DrUrah:DrUox molar ratios. 
(e) Uox activity in potassium phosphate (KP) buffer (100 mM, pH 7.6) and Borate (B(OH)3) buffer (50 mM, pH 
9.2) in the absence (filled bars) and in the presence (striped bars) of equimolar DrUrah. (f) Formation and decay of 
the HIU product of the Uox reaction monitored by absorbance at 320 nm in KP and B(OH)3 buffers in the absence 
and in the presence of equimolar DrUrah.
www.nature.com/scientificreports/
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monomers assemble into a dimer by a two-fold axis to form a β 16α 8 barrel (Fig. 5a). The main dimerization inter-
face is an antiparallel β -sheet formed by the N-terminal (aa 8–20) and C-terminal (aa 282–293) β strands of two 
subunits (Supplementary Fig. S6). Several hydrogen bonds involving backbone atoms link the two β strands. Other 
electrostatic interactions involve the residue side chains of different subunits such as T65-T174 and N68-T175. 
The identity of such residues is typically conserved in Uox multiple alignments (Supplementary Fig. S7). The 
tetramerization interface has two main regions of interactions. One region involves mainly side chain interactions 
(H-bonds and salt bridges) between polar residues such as R28-D273, E37-Y259, K75-S270. This region of inter-
action comprises a loop between strands β 10 and β 11 that is conserved in vertebrate proteins, but not in other 
Uox with known structure. A second region involves a short antiparallel β -sheet formed by part of the strands β 5 
(aa 125–127) and β 7 (aa 157–159). Phenylalanine 216, a residue strictly conserved in Uox alignment, is not part 
of the tetramer interface, but establishes main chain and side chain interaction with lysine 158 of the tetramer 
interface (Supplementary Fig. S6).
In the crystal structure, chains A-C and B-D at the tetramer interface are connected by a disulfide bond involv-
ing Cys129 (Supplementary Fig. S8), a residue not conserved in Uox sequences (see Supplementary Fig. S7). The 
geometrical parameters of the disulfide, classify it as having a Left-Handed Staple conformation (+ LHStaple), a 
rare bond characterized by a high strain energy (Supplementary Table 2). SDS-PAGE analysis provided evidence 
Figure 3. Binding and activity of DrUox and F21α mutant. (a) SDS-PAGE of the protein fractions of 
xanthine-agarose affinity chromatography for the wt (upper panel) and mutant (lower panel) DrUox; M: 
marker; S: soluble cell fraction; FT: Flow-Through; E1-E3: Elution fractions: R: Resin (b) Dependence of the 
initial rate of oxidation on urate concentration of wild type (closed circles) and mutant F216S (open circles) 
DrUox; data points were fitted to the Michaelis-Menten equation. (c) Dependence of the initial rate of oxidation 
on urate concentration of wild type (left panel) and mutant F216S (right panel) DrUox in the presence of 
increasing xanthine concentrations. Data points were fitted with a global fit to the equation for the competitive 
inhibition model.
Urate Xanthine
KM (μM) kcat (s−1) kcat/Km ( M−1 s−1) Ki (μM)
Wild Type 11 ± 1 3.95 ± 0.09 3.6 * 105 4.3 ± 0.27
F216S 284 ± 31 3.99 ± 0.1 1.4 * 104 59.2 ± 8.2
Table 2.  Kinetic and inhibition constants for wt and mutant DrUox.
www.nature.com/scientificreports/
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of the presence in solution of a inter-subunit covalent link under non-reducing conditions; however, DrUox sta-
bility, as measured by retention of enzymatic activity at different temperatures, was substantially increased under 
reducing conditions (Supplementary Fig. S8).
The active sites (four in the tetramer) are located at the dimerization interfaces. F216 is not directly involved 
in substrate binding, but is involved in a cluster of hydrophobic interactions with active site residues (Fig. 5b). In 
particular, this cluster comprises conserved residues K159, F184, V188, V229, R182, and F165. Through its gua-
nidino group, R182 establishes a bidentate interaction with the urate substrate. The aromatic ring of F165 forms 
a stacking interaction with the urate purine ring, while V229 borders the active site cleft and makes a backbone 
interaction with the substrate. The substitution of F216 with a polar serine residue is expected to perturb this 
hydrophobic cluster and impact the formation of the Michaelis complex.
Discussion
Together with HIU hydrolase (Urah) and OHCU decarboxylase (Urad) from the same organism26,27, the zebraf-
ish urate oxidase characterized here constitutes the enzymatic complement of uricolysis. At variance with the 
administration of the Uox alone, a pharmaceutical preparation containing such a complete uricolytic system 
with appropriate chemical modifications (L. Ronda et al., manuscript in preparation) would ensure physiological 
conversion of urate into (S)-allantoin and prevent the accumulation of reactive intermediates of urate oxidation.
An unexpected feature of the DrUox structure was the presence of a disulfide bridge covalently linking dif-
ferent subunits at the tetramer interface. This information is relevant for the in vitro activity and the practical 
use of the enzyme as we conclude that the reduction of the disulfide is likely to occur within the cell. Although 
Figure 4. Quaternary states of DrUox and F216S mutant in solution. (a) High-performance size-exclusion 
chromatography analysis of wt (solid line) and F216S (dashed line) DrUox; gray dropped lines represent 
the predicted retention times for the different oligomeric states (from left to right: octamer, tetramer, dimer, 
monomer). Calibration curve obtained from the separation of standard solutions of ferritin (440 kDa), GAPDH 
(144.2 kDa), conalbumin (75 kDa), ovalbumin (43 kD) and carbonic anidrase (29 kDa). (b) Activities of wild 
type (left panel) and mutant F216S (right panel) DrUox tested at increasing concentration of enzyme in the 
presence of 27 μ M and 400 μ M urate, respectively; reactions were carried out in the presence of equimolar 
DrUrah at 25 °C.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:38302 | DOI: 10.1038/srep38302
this feature has not been previously observed in natural Uox, a disulfide bond has been introduced on purpose 
at the tetramer interface of a bacterial Uox by site-directed mutagenesis. Interestingly, this engineered protein 
showed increased thermal stability that was negatively affected by reducing compounds35. By contrast, the pres-
ence of reducing compounds increased the functional stability of DrUox. A possible explanation to the different 
contribution of disulfide bonds to Uox stability is that the bond introduced in Bacillus sp. TB-90 is located at the 
main dimer-dimer interface while in our case it is located in a region that is normally not involved in extensive 
inter-subunit interactions. Relocation of the disulfide bond in DrUox by site-directed mutagenesis could be a 
strategy to improve thermal stability, if required. Evidence in the crystal and in solution indicates that DrUox 
is prone to the formation of non-native intra- and inter-chain disulfide bonds. A tendency to the formation of 
non-native disulfide bonds has been reported for other eukaryotic Uox, and might account in part for the com-
plex mechanism of its irreversible thermal denaturation36. The effect of reducing agents suggests that the presence 
of free thiols is a preferred condition for the DrUox protein. As for other animal Uox, the zebrafish enzyme has 
been selected by evolution to function inside peroxisomes, organelles in which the redox state is more reducing 
than in the cytosol37. The reducing conditions of the peroxisome lumen limit the threat of cysteine oxidation and 
the formation of non-native disulfide bonds, providing a possible rationale for the more frequent usage of this 
amino acid in eukaryotic Uox (Supplementary Fig. S8).
The addition of the Urah enzyme in the spectrophotometric assay for the Uox reaction allowed elimination of 
the interference of the HIU product and a more reliable measure of the enzymatic activity in physiological buffers. 
The modified spectrophotometric assay was used for a detailed comparison of the enzymatic activity of the wt and 
F216S mutant in order to shed light on the genetic modifications that preceded the loss of the urate degradation 
pathway in hominoid evolution. We found that this mutation does not change the enzyme turnover number (kcat), 
but increases about 25 times its Michaelis constant (KM). Structural and biochemical evidence suggests that the 
Phe→ Ser substitution impacts the formation of the enzyme-substrate complex through the alteration of a cluster 
of hydrophobic residues involved in substrate binding.
Figure 5. Structure of DrUox tetramer. (a) Side and top view of the DrUox structure in cartoon representation 
colored by chains. (b) Detail of active site at the interface between chains A (green) and B (cyan); residues 
involved in a cluster of hydrophobic interactions with F216 are shown as spheres according to their Van der 
Waals radii. Each residue in the cluster is at < 5.5 Å distance from another hydrophobic residue. The urate 
molecule (sticks) was docked by structural superimposition with the enzyme-substrate complex of Aspergillus 
flavus (PDB id 3BJP).
www.nature.com/scientificreports/
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Maximum likelihood reconstruction of ancestral sequences suggests the possible occurrence of a nonsense 
mutation (R107*) before the split of great and lesser apes (see Fig. 1). A caveat to this conclusion is that the nucle-
otide substitution model used in the analysis does not account for the hypermutability of the CpG dinucleotide. 
Several stop codons observed in the Uox pseudogenes of extant hominoids originate from mutation of CGA Arg 
codons into TGA opal stop codon; vulnerability of methylated cytosine to spontaneous deamination to thymine 
at CpG sites increases the possibilities of recurrent C→ T mutations4. This increased mutability is confirmed by 
the substitutions observed in our hominoid data set: with respect to eleven CpG dinucleotide positions in the 
reconstructed hominoid ancestor sequence, seven cases of single C→ T mutations and two cases of recurrent 
C→ T mutations are observed in the sense strand of extant hominoid sequences. However, the hypothesis of late 
appearance of a stop codon at position 107, would require independent fixation of the mutation in three lineages. 
As there are two early nonsense mutations, R18* and R33*, fixed in the Uox sequence of lesser and great apes, 
respectively4, the independent fixation of the R107* mutation should have occurred by random genetic drift. 
Although this hypothesis cannot be ruled out, the pattern of sense and nonsense codons at position 107 could be 
explained by a back mutation in the Homo-Pan lineage, or with a single mutation and incomplete assortment of a 
polymorphic allele. This scenario requires maintenance of the polymorphism for a long time (~10 myr) and thus 
the presence of balancing selection. Some examples are known of the long-term maintenance of polymorphisms 
during ape evolution. For instance, the polymorphism at the ABO blood groups is thought to have originated 
before the ape last common ancestor and been maintained for > 20 myr38.
Analysis of available genomes indicates that urate oxidase cannot be easily lost in vertebrate organisms. Even 
uricotelic vertebrates such as birds and some reptiles conserve a Uox gene without obvious inactivating mutations23. 
Among the sequenced mammals, hominoids are the only group with evidence of Uox pseudogenization. The 
detrimental effect of Uox inactivation in mammals is well demonstrated by the Uox KO mouse, which is affected 
by perinatal mortality caused by obstructive nephropathy due to urate deposition in the kidney39. As a whole, 
this evidence has suggested that during primate evolution other genes related to purine metabolism changed “to 
accommodate the increased levels of uric acid”5. As demonstrated by the mouse Uox KO phenotype, the renal 
handling of urate is key to the management of high urate concentrations. Urate homeostasis is regulated by a 
set of membrane transporters located in the epithelial cells of the kidney (and to a lesser extent of the intestine) 
involved in secretion and absorption5,6. In human and apes, 90% of the filtered urate is reabsorbed along the 
nephron. Lower levels of renal reabsorption have been described in other primates, rodents and the dog, while 
in other mammals (e.g. pig) urate is not reabsorbed. In organisms that have lost the urate degradation path-
way, renal reabsorption maintains high urate concentration in the blood while preserving the kidney function. 
This is underpinned by the association of nephrolithiasis and kidney failure with loss-of-function mutations 
of membrane transporters SLC22A12 and SLC2A9 involved in urate reabsorption, as observed in hereditary 
hypouricemia40,41.
The Uox gene was under strong and relatively constant purifying selection during most of the primate evolu-
tionary tree, including (at least part of) the branch leading to the last common ancestor of hominoids; the selec-
tion pressure relaxed abruptly in the great and lesser apes lineages, with dN/dS values close to the unit, as typical 
of pseudogenes (see Fig. 1 and Table 1). A similar analysis conducted on the two other genes of the urate degrada-
tion pathway, Urah and Urad, shows a comparable trend, with a relaxation of the purifying selection after the split 
of hominoids. The fact that the inferred dN/dS value for these two genes is still below the unit, could indicate that 
the pseudogenization of the two other genes of the pathway was consequent to the Uox psuedogenization23. In 
summary, dN/dS analysis does not suggest a progressive decline of the selection pressure acting on genes involved 
in urate degradation during primate evolution. As already pointed out25, this observation is difficult to reconcile 
with the hypothesis of fixation of deleterious missense mutations in the Uox sequence. The possibility for a dele-
terious mutation to be fixed by random drift increases in small populations. It should be noted, however, that the 
ancestral population of the hominoid is estimated to be relatively large, about five time larger than the ancestral 
population of the genus Homo42.
Mutations decreasing the Uox catalytic efficiency are expected to increase the in vivo concentration of urate. 
Such mutations could have been perpetuated by evolution in spite of a detrimental effect on the Uox function 
and the threat posed by the elimination of a poorly soluble molecule, because of the compensatory benefit of 
high serum urate concentration. Numerous hypotheses on the possible advantages of elevated serum urate levels 
have been put forward43–45, although a clear demonstration of a beneficial role of urate in humans is still lacking. 
In this scenario, the accumulation of detrimental mutations in Uox, culminating in the complete inactivation of 
the gene, was the evolutionary force driving a change of purine metabolism in hominoids. Based on biochemical 
and sequence analysis data, we propose an alternative scenario in which the modification of the renal handling of 
urate preceded the genetic modifications in the Uox gene. In the presence of increased levels of circulating urate 
due to renal reabsorption and possibly to changes in the dietary habits46, mutations increasing the Uox KM for 
the substrate would have been neutral or even adaptive. In turn, a renal system able to handle high levels of urate 
could have permitted the complete dismissal of the degradation pathway by gene inactivation.
It is generally assumed that the kinetic parameters of enzymes, particularly kcat and KM, are shaped by evolution 
according to the organism’s needs47,48. For some enzymes involved in very important pathways the catalytic effi-
ciency, expressed as kcat/KM, approximates the highest theoretical values (108–109 M−1 s−1)49. However, the kcat/KM 
values for the large majority of enzymes lie in the range of 103–106 M−1 s−1. In this respect, Uox is an example of 
the ‘average’ enzyme —that is an enzyme that is not under strong selective pressure for catalytic efficiency48. On 
the other hand, the magnitude of the Michaelis constant (KM) is in correlation with the in vivo concentration of 
the substrates, suggesting evolutionary adaptation of KM values to the reactant concentrations47,50. This implies 
that as a consequence of an increased physiological level of a metabolite, mutations increasing the KM (and thus 
decreasing the enzyme ‘catalytic efficiency’) are not expected to have a deleterious effect on the fitness. The F222S 
mutation is not observed in extant Uox proteins. However, there are natural Uox enzymes with KM values similar 
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to that observed in the DrUox mutant. Interestingly, a high KM for urate (~300 μ M) has been reported for the 
enzyme of Bacillus fastidiosus, a bacterium specialized for growth in urate-rich media30. Also, similarly to the 
mutant DrUox, the B. fastidiosus protein has a high inhibition constant for xanthine (Ki = 41 μ M).
Our results suggest that the last functional urate oxidase in hominoid evolution had a rather high Michaelis 
constant, possibly near to the upper end of the normal range of urate in the human serum. As the goal of an 
enzymatic therapy should be the maintenance of urate concentrations in a physiological range, a protein with this 
catalytic property could be considered for a long-term enzymatic treatment with urate oxidase.
Methods
Gene cloning and mutagenesis. A cDNA encoding the complete sequence of zebrafish urate oxi-
dase (IMAGE:100059545) was PCR-amplified using a high fidelity thermostable DNA polymerase (Deep 
Vent DNA polymerase, New England Biolabs) and two sequence-specific primers: an upstream primer 
(5′ -CATATGGCCACTACCTCAAATC-3′ ) and a downstream primer (5′ -GGATCCTTGTCTTCACATTCTG-3′ ). 
The amplification product cloned into pNEB193 vector (New England Biolabs) was digested with BamHI and 
NdeI and subcloned into the expression vector pET11b. The urate oxidase mutant F216S was obtained by site-di-
rected mutagenesis using a high fidelity thermostable DNA polymerase (Pfu Ultra II Fusion HS DNA polymer-
ase, Stratagene) and the primer 5′ -CCGTCATTCAAAAGTCTGCAGGACCCTACGATCG-3′ and its reverse 
complementary. The plasmid pET11b-DrUox was used as template and the reaction products were treated with 
DpnI (Stratagene) to digest the parental DNA template. For the production of His-tagged proteins, the sequences 
encoding DrUox wild type or F216S mutant were isolated by NdeI-BamHI digestion from the pET11b vector and 
inserted into pET28b (Novagen), in frame with the sequence coding for the N-terminal 6xHis tag. The resulting 
expression vector was electroporated into E. coli BL21-CodonPlus(DE3) competent cells.
Protein expression and purification. The expression in E. coli BL21 codon plus (DE3) strain in LB 
medium was induced by adding 1 mM IPTG. After 16 hours incubation at 20 °C, cells were resuspended in 
100 mM potassium phosphate (KP) buffer at pH 7.6, in the presence of 300 mM NaCl, 10% glycerol, 0.2 mM 
PMSF, 0.2 mM benzamidine, 1.5 μ M pepstatin A and 1 mg/ml lysozyme and incubated under agitation at 4 °C for 
45 minutes. The suspensions were then lysed by sonication and centrifuged at 16000 g for 30 min. For the purifica-
tion of the untagged DrUox, soluble cell fraction was applied to a xanthine agarose resin (X3128, Sigma-Aldrich) 
packed column previously equilibrated with 100 mM KP at pH 7.6. The column was washed with the same buffer 
and then the protein was eluted with phosphate buffer containing 0.5 mM urate. The His-tagged wt and mutant 
proteins were purified by affinity chromatography on cobalt-charged resin (Talon, Clontech). A washing step 
was performed with 50 mM sodium phosphate, 300 mM NaCl, 20 mM imidazole, pH 7.6, prior to eluting the 
6xHis-tagged protein from the resin with 50 mM sodium phosphate, 150 mM NaCl, 200 mM imidazole, pH7.6. 
Purified untagged and His-tagged proteins were diafiltered and concentrated in 100 mM KP, 150 mM NaCl buffer, 
pH 7.6, by 30 kDa Amicon Ultra-15 centrifugal filter devices (Merck-Millipore). Wt and F216S DrUox were 
finally filtered with 0.2 μ m filter units to eliminate possible aggregates. Proteins were divided in small aliquots, 
flash frozen in liquid nitrogen and stored at − 80 °C.
Crystallization, data collection and structure determination. For protein crystallization, a 10 mg/ml 
solution of untagged DrUox (10 mM Tris-HCl, pH 7.6, 1 mM EDTA) was diluted 1: 2 with Str. Screen 1 n. 8 (0.1 M 
Tris-HCl, pH 8.5, 8% PEG 8000). Hanging drops were equilibrated by vapor diffusion against the same reservoir 
solution. Single crystals were obtained in about a week of incubation at room temperature. Protein crystals were 
flash frozen in a cryogenic nitrogen stream at 100 K. The dataset was collected at the ID23–2 beam-line of the 
ESRF Synchrotron Radiation Facility in Grenoble (France). The best crystals diffracted to 2.8 Å resolution. DrUox 
crystallizes in the space group P21, with cell parameters a = 85.341 Å, b = 127.415 Å, c = 132.604 Å, β = 102.21°. 
The asymmetric unit contains two tetramers, corresponding to a Matthews coefficient of 2.68 Å3/Da and a solvent 
content of about 54% of the crystal volume. The correct solution was found using the model of urate oxidase 
from Aspergillus flavus (PDB ID 1R56)15. Molecular replacement was performed with Phaser51. Refinement was 
performed using the CNS package52 and, in the final steps, Phenix53. Several cycles of automatic refinement and 
manual model building by Coot54 reduced the crystallographic R factor to the final value of 0.1976/0.2587 for all 
the data from 83.3 Å to 2.8 Å resolution. The electron density was quite well defined for all residues from Gly8 
to Pro294. The quality of the model was assessed using the Molprobity program (Phenix), and all the criteria 
were as expected for a structure at this resolution. Data collection and refinement statistics are summarized in 
Supplementary Table S1.
Oligomeric state and disulfide bond analysis. The oligomeric state of wt and mutant Uox in native 
conditions was analyzed on a HPLC-SEC Superdex 200 increase 3.2/300 column (GE Healthcare) by loading 
about 13 μ g of each sample. A calibration curve was determined by running five commercial standards for SEC 
(blue dextran, ferritin, conalbumin, ovalbumin and carbonic anidrase, GE Healthcare) and the home-made 
standard glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The elution was monitored at 280 nm. The pres-
ence of inter-subunits disulfide bonds was assessed by SDS-PAGE analysis under reducing and non-reducing 
conditions. Purified DrUox was alkylated through 30 minutes-incubation with 0.125 M iodoacetamide (IAM, 
Bio-Rad) at room temperature in the dark and then the excess of IAM was inactivated exposing the solution 
at light for 30 minutes. Native and alkylated DrUox were boiled at 95 °C for 5 minutes in denaturing buffer (6% 
(v/v) SDS, 30% (v/v) glycerol, 0.006% (v/v) Bromophenol Blue, 0.185 M Tris HCl, pH 6.8) in reducing (15% 
β -mercaptoethanol) and non reducing conditions. All the samples were loaded on 12% SDS-PAGE. The analysis 
of the geometrical parameters of the disulfide bond was performed with the UNSW online tool55 based on the 
atomic coordinates of DrUox. The number of cysteines in Uox proteins of different taxonomic divisions was 
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determined for 1385 sequences clustered at 80% similarity with the cdhit program using the pepstat program of 
the Emboss package. Data were plotted using the geom_boxplot and geom_jitter functions of the ggplot2 library 
of the R package.
Activity assays. Catalytic activity measurements were carried out with a Cary 400 Varian UV-visible spec-
trophotometer with a thermostated cell-holder, at 25 °C. Reactions were started with the addition of the enzyme 
to a solution of 100 mM KP, pH 7.6, in the presence of different concentrations of urate as substrate. Reaction 
rates were determined in the presence of 1:1 molar ratio of Urah from zebrafish26 to avoid the interference of the 
Uox reaction product, 5-hydroxyisourate. The activity was monitored at the fixed wavelength of 292 nm, corre-
sponding to the absorbance peak of urate, except for the dependence of F216S activity on xanthine concentration, 
registered at 302 nm in order to reduce the absorption interference of xanthine. Enzymatic activity dependencies 
on increasing substrate concentrations in the presence of different xanthine concentrations were globally fitted to 
the equation for competitive inhibition.
Calculation of HIU and OHCU spectra and time course kinetic analysis. Approximate absorption 
spectra of the unstable intermediate HIU and OHCU were obtained by kinetic analysis of the time-dependent 
spectral evolution of 0.1 mM urate in the presence of Uox and Urad, or Uox and Urah, respectively. The time- 
dependent spectra were fitted to a sequential model of intermediate formation and decay using the fitModel 
function implemented in TIMP library56 of the R package. Time course kinetic analysis of the Uox reaction in the 
presence and in the absence of Urah was conducted by fitting single wavelength kinetics to the Schell-Mendoza 
equation32 using the Lambert-W function implemented in the Gnu Scientific Library (gsl) of the R package.
Reconstruction of primate Uox sequences from assembled genomes and short sequence reads. 
Genomic regions containing the Uox sequences were identified by homology searches (tblastn) in assembled 
genomes of the primate division using the reference protein sequence of Macaca fascicularis as a query. Portions 
encompassing 10 k nt. upstream and downstream the coding or pseudo-coding sequence boundaries were 
extracted for further analysis. Short SOLID reads (50 nt.) of four gibbon species (Hylobates moloch, Hylobates 
pileatus, Symphalangus syndactylus, Hoolock leuconedys) with no assembled genomes29 were downloaded from the 
ncbi Sequence Read Archive (http://www.ncbi.nlm.nih.gov/sra) and converted to basespace using the fastq-dump 
utility of the SRA toolkit. The reads were then mapped on the reference N. leucogenys genome using the BBmap 
program (http://bbmap.sourceforge.net/). To facilitate the identification of the reads mapping to the Uox gene, 
the corresponding region of N. leucogenys (CDS ± 10 k nt.) was included as separated sequences in the reference 
assembly and masked in the chromosome sequences. Reads mapped to the Uox locus were filtered from the 
SAM format output of bbmap using Linux grep and converted to sorted BAM format using SAMtools (Ver. 1.2) 
(http://samtools.sourceforge.net/). Sequence variation with respect to the reference sequence was determined 
using Bcftools (Ver 1.2), and a consensus sequence of mapped reads was obtained with the vcfutils.pl utility. 
The Genewise program28 was used to reconstruct the exonic and intronic structures of genes or pseudogenes. 
Genewise was run with search parameters adapted for pseudogene reconstruction: the probability of indels and 
substitutions was increased (-indel 1e-3 -susbs 1e-3) and a splice site model was used (-nosplice_gtag) instead 
of the default flat model to allow for splice site mutations. Also, the gap extension penalty was increased (-e 5) to 
avoid the insertion of gaps at the intron/exon boundaries in the presence of sub-optimal splice sites.
Reconstruction of ancestral sequences and dN/dS analysis. The Uox coding and pseudo-coding 
sequences were aligned with MACSE using different alignment parameter for gene and pseudogenes57. Ancestral 
sequences were reconstructed based on a rooted primate ultrametric tree58 and the alignment of extant Uox 
sequences using the Bayesian method (RateAncestor = 1) implemented in the baseml program of the PAML 
package59. Ancestral probabilities were calculated using a local molecular clock model assuming a long-term 
rate variation in correspondence with the hominoid lineage. The rates of non-synonymous (dN) and synony-
mous substitutions (dS) were calculated along the branches of the primate tree using the PAML codeml program. 
Models assuming persistent variations of dN/dS ratios on different branches of the primate tree were compared 
by the Likelihood-ratio (LTR) test.
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